[go: up one dir, main page]

WO2023177234A1 - Composition pour la prévention et le traitement d'oedème inflammatoire, comprenant un extrait d'aster glehni fr schm. comme principe actif - Google Patents

Composition pour la prévention et le traitement d'oedème inflammatoire, comprenant un extrait d'aster glehni fr schm. comme principe actif Download PDF

Info

Publication number
WO2023177234A1
WO2023177234A1 PCT/KR2023/003521 KR2023003521W WO2023177234A1 WO 2023177234 A1 WO2023177234 A1 WO 2023177234A1 KR 2023003521 W KR2023003521 W KR 2023003521W WO 2023177234 A1 WO2023177234 A1 WO 2023177234A1
Authority
WO
WIPO (PCT)
Prior art keywords
muscle
extract
asterium
vulgaris
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2023/003521
Other languages
English (en)
Korean (ko)
Inventor
서홍석
이용직
김형자
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Science and Technology KIST
Korea University Research and Business Foundation
Original Assignee
Korea Institute of Science and Technology KIST
Korea University Research and Business Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Science and Technology KIST, Korea University Research and Business Foundation filed Critical Korea Institute of Science and Technology KIST
Publication of WO2023177234A1 publication Critical patent/WO2023177234A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles

Definitions

  • the present invention relates to a composition for the prevention and treatment of muscle disease, etc., containing an extract of Sagebrush as an active ingredient.
  • Muscles are largely divided into skeletal muscle, cardiac muscle, and smooth muscle.
  • skeletal muscle is the tissue present in the largest amount in the human body, accounting for 40-45% of body weight.
  • Skeletal muscles are attached to bones through tendons and play a role in producing bone movement or force.
  • One muscle is made up of numerous muscle fibers, which in turn are made of numerous myofibrils made up of actin and myosin. When actin and myosin overlap each other, the length of the muscle shortens or lengthens, causing contraction and relaxation of the overall muscle.
  • An increase in myofiber size means an increase in muscle fiber thickness, resulting in muscle growth.
  • Type IIA The types of muscle fibers that make up muscles are mainly divided into Type I, Type IIA, and Type IIB depending on the metabolic process that generates ATP and the contraction speed.
  • 'Type I muscle fibers' have a slow contraction speed and contain a large number of myoglobin and mitochondria, making them suitable for continuous, low-intensity aerobic activity.
  • Type I muscle fibers are red in color, so they are also called red muscles, and the soleus muscle is a representative example.
  • 'Type IIB muscle fibers' have a fast contraction speed, so they are used for very short but high-intensity anaerobic exercise, and have a white color due to their low myoglobin content.
  • ‘Type IIA muscle fibers’ have intermediate characteristics between the two muscle fibers mentioned above. As we age, not only does the composition of type I and II muscle fibers in each muscle area change, but all types of muscle fibers decrease.
  • Skeletal muscle has the characteristic of being regenerated and maintained depending on the environment, but this characteristic is lost with age, and as a result, not only muscle mass decreases but also strength is lost as aging progresses.
  • a vicious cycle of musculoskeletal degeneration begins, based on weakening muscle strength for physical activity.
  • Reduced walking speed and weakened grip strength are the main symptoms and indicators of decreased muscle mass, which can additionally lead to falls, fractures, joint damage, metabolic disorders, and cardiovascular disease. This decrease in muscle mass can be visually represented as a decrease in the volume of muscle fibers, that is, muscle atrophy.
  • Decreased muscle mass can occur naturally as the body ages, and can occur due to muscle underuse or lack of exercise, or due to other pathological conditions (cachexia, sepsis, starvation, chemotherapy, excessive exposure to stress hormones). , cerebrovascular disease, etc.) may occur secondaryly. This can be lumped into muscle cell atrophy due to the anti-anabolic and catabolic effects of Type I and II muscle fibers.
  • Untreated muscle loss can be a fatal health problem in itself, and can also cause secondary problems that cause harmful metabolic diseases and sharply reduce activity. This can be a particularly serious problem in older people who already have age-related deficiencies in muscle mass, so there is a very high social need to solve this problem.
  • Aster glehni which grows wild on Korea's Ulleungdo Island, is about 1 m tall, has fine hairs on its stems, and rhizomes grow sideways.
  • the leaves are alternate, and when flowers bloom, the leaves at the bottom fall off and are oval-shaped with short stems.
  • the stem leaves are alternate and long oval shaped, with a length of 1319 cm and a width of 46 cm. It also has irregular sawtooth edges, hairs on both sides, and glandular spots on the back.
  • the flowers bloom from August to October, are white, have a diameter of about 1.5 cm, and hang in corymbs at the ends of the main stem and branches.
  • Aster glehni has the effect of removing wind, reducing fever, detoxifying, removing phlegm, and stopping coughing. It is also known to be able to treat colds caused by wind heat, tonsillitis, bronchitis, fever, poisonous poison, snake bites, and bee stings.
  • the anti-obesity KR 10-1523820
  • skin moisturizing KR 10-2327847
  • cognitive function improvement KR 10-2056300
  • the present inventors determined that the demand for pharmaceutical compositions and health functional food compositions that have the effect of preventing muscle loss and improving muscle function will continue to increase in modern society where aging continues, and screened natural products that can show the effect of improving muscle function.
  • the present invention was completed by confirming that Aster extract can increase ATP production by activating mitochondria in skeletal muscle, inhibit muscle loss, and simultaneously enhance muscle synthesis.
  • the technical problem to be achieved by the present invention is to provide uses of the Asterium vulgaris extract for preventing and treating muscle diseases, promoting muscle differentiation, muscle regeneration and muscle strengthening, and increasing muscle mass and promoting muscle creation.
  • the present invention provides a pharmaceutical composition for preventing or treating muscle disease, comprising an extract of Asterium vulgaris as an active ingredient.
  • the muscle disease may be a muscle disease caused by decreased muscle function, muscle loss, muscle atrophy, muscle wasting, or muscle degeneration.
  • the muscle disease includes atony, muscular atrophy, muscular dystrophy, myasthenia gravis, cachexia, rigid spine syndrome, and muscular dystrophy. Selected from the group consisting of amyotrophic lateral sclerosis (Lou Gehrig's disease), rigid spinsesyndrome, Charcot-Marie-Tooth disease, and sarcopenia due to aging or cerebrovascular disease. There may be one or more of the above, and the sarcopenia includes primary and secondary sarcopenia.
  • the present invention provides a pharmaceutical composition for promoting muscle differentiation, muscle regeneration, or muscle strengthening, comprising an extract of Asterium vulgaris as an active ingredient.
  • the present invention provides a pharmaceutical composition for increasing muscle mass or promoting muscle formation, comprising an extract of Sagebrush as an active ingredient.
  • the present invention provides a food composition for promoting muscle differentiation, muscle regeneration, or muscle strengthening, which contains an extract of Sagebrush as an active ingredient.
  • the present invention provides a food composition for increasing muscle mass or promoting muscle production, comprising an extract of Sagebrush as an active ingredient.
  • the present invention provides a food composition for improving muscle function, comprising Aster extract as an active ingredient.
  • the present invention provides a method of treating muscle disease comprising the step of administering an extract of Sagebrush to an individual with advanced muscle weakness and/or muscle loss, or to an individual with a genetic predisposition related to muscle disease or to an individual suffering from the disease. do.
  • the present invention provides the use of aster extract for the manufacture of drugs for the prevention and treatment of muscle diseases.
  • the Asterium aster extract may reduce the expression of Myostatin, which destroys muscle proteins.
  • the Sagebrush extract may increase the expression of MyoD, which produces muscle proteins and promotes differentiation into muscle cells.
  • the Asteria serrata extract may be obtained from Asteria serrata leaves.
  • the Sagebrush extract is water, C 1 to C 4 lower alcohol, n-hexane, ethyl acetate, acetone, butylacetate, 1,3-butylene glycol, methylene chloride, and It may be extracted with one or more solvents selected from the group consisting of mixed solvents.
  • the Sagebrush extract may be an ethyl acetate fraction of an extract extracted with a C 1 to C 4 lower alcohol as a solvent.
  • the prevention or treatment method may include measuring the muscle strength of the subject to be administered before and/or after administration of the Asterium vulgaris extract.
  • the prevention or treatment method may include measuring the degree of muscle loss of the subject to be administered before and/or after administration of the Asterium vulgaris extract.
  • the prevention or treatment method includes measuring the symptoms of muscle disease or the level of biomarkers of the disease in the subject to be administered before and/or after administration of the Asterium vulgaris extract. can do.
  • the Sagebrush extract which has the effect of preventing and treating muscle diseases according to the present invention, improves the function of skeletal muscles, reduces the expression of proteins that induce muscle loss, and increases the expression of proteins that promote muscle development and growth. It has the effect of improving, preventing, and treating muscle diseases.
  • the Sagebrush extract of the present invention is derived from a natural product that has been proven to be highly safe for a long time, and has the advantage of having very few or no side effects when used. Accordingly, in addition to the use of the composition of the present invention for the treatment of muscle diseases, it is also used for medicinal purposes to suppress muscle loss, increase muscle mass, and improve muscle function, for external use in pharmaceuticals, for cosmetic materials, for enhancing physical vitality, and for functional biomaterials. It is expected to be used in a variety of ways, including for functional food materials.
  • Figures 1a and 1b show the results of measuring the mitochondrial function of C2C12 cells treated with Asterium vulgaris extract through XFp analysis.
  • Figure 2 shows the results confirming that the concentration of ATP in skeletal muscle tissue increased in mice administered the Asterium aster extract.
  • Figure 3 shows the results of an immunohistochemistry test confirming that the expression of myoglobin in skeletal muscle tissue was increased in mice administered with Aster extract.
  • Figure 4 shows the results of an immunohistochemistry test confirming that the expression of myoD in skeletal muscle tissue was increased in mice administered with Aster extract.
  • Figure 5 shows the results of an immunohistochemistry test confirming that the expression of myostatin in skeletal muscle tissue was reduced in mice administered Aster extract.
  • the present inventors completed the present invention by screening natural products that can prevent muscle loss and improve muscle function, and confirmed the effects of improving mitochondrial function in skeletal muscle, inhibiting muscle loss, and promoting muscle synthesis in the Asterium vulgaris extract.
  • the present inventors performed XFp analysis by treating the C2C12 cell line, a mouse skeletal muscle cell line, with aster extract. As a result, increased oxygen consumption was confirmed, showing that aster aster activates mitochondrial function in skeletal muscle. There was (Example 2).
  • mice administered the Sagebrush extract showed higher ATP levels in skeletal muscle tissue compared to the non-administered group, a result consistent with the in vitro experiment (Example 3-2).
  • immunohistochemical staining of skeletal muscle tissue slides was performed to confirm the expression levels of Myoglobin, MyoD, and Myostatin in skeletal muscle tissue.
  • administration of Asterium vulgaris extract increased the expression levels of Myoglobin and MyoD and the expression level of Myostatin. was confirmed to be reduced (Example 3-3).
  • Myostatin is a gene related to muscular dystrophy and is known to inhibit skeletal muscle growth by destroying muscle proteins. Additionally, MyoD is known to produce muscle proteins and have the ability to induce muscle differentiation. Myoglobin is an oxygen-binding protein expressed in skeletal muscle and myocardium and is essential for muscle cells to produce the energy needed for muscle contraction.
  • the present inventors confirmed that the Asterium aster extract acts on skeletal muscle to improve the function of the skeletal muscle itself, suppresses muscle decline, and at the same time contributes to the development and growth of muscle, and found that the Asterium asterium extract acts on skeletal muscle to prevent and prevent muscle diseases. It can be used for therapeutic purposes, for promoting muscle differentiation, for muscle regeneration, for muscle strengthening, for increasing muscle mass, and for promoting muscle creation.
  • muscle disease is caused by decreased muscle function, muscle loss, muscle atrophy, muscle wasting or muscle degeneration, and includes atony, muscular atrophy, muscular dystrophy, myasthenia gravis, cachexia, Rigid spine syndrome, amyotrophic lateral sclerosis, rigid spine syndrome, Charcot-Marie-Tooth disease, and sarcopenia. It may be any one or more selected from the group consisting of:
  • muscular dystrophy refers to atrophy of skeletal muscles as symptoms such as disuse atrophy of muscles, absence of mechanical stimulation and denervation of skeletal muscles, cachexia, and drug induced muscle atrophy. ), malnutrition induced muscle atrophy, and muscular dystrophy.
  • 'disuse atrophy of muscles' includes a decrease in muscle thickness due to activity limitations due to aging, disease, etc., long periods of bed rest, use of splints, etc., and refers to a decrease in the thickness of muscles in the central nervous system or peripheral nerves. It is accompanied by various clinical diseases such as injury, cancer, and sepsis, as well as long-term bed rest, cast immobilization of limbs, and the aging process. In general, muscle atrophy is accompanied by physiological, histochemical and biochemical changes caused by a decrease in muscle proteins and can result in intrinsic dysfunction of skeletal muscle.
  • 'denervated muscle cells result in quantitative reduction and dysfunction of mitochondria, increased production of mitochondrial reactive oxygen species (ROS), and apoptosis of muscle cells due to oxidative damage. may be the result of an increase.
  • ROS mitochondrial reactive oxygen species
  • 'cachexia' is one of the symptoms of severe systemic weakness that can be seen in the terminal stages of cancer, tuberculosis, hemophilia, etc., and can cause rapid contraction.
  • 'muscular dystrophy' is a disease whose main symptoms are muscle atrophy and muscle weakness caused by the absence of dystrophin-glycoprotein complex, a component of the rhabdoid plasma membrane, due to a genetic mutation.
  • the muscular atrophy includes muscle atrophy caused by cortisol, a substance that can be secreted in the body due to various acute stresses, and steroids caused by adverse reactions to synthetic corticosteroids. It includes muscle atrophy and dysfunction due to myopathy, damage to muscle parenchyma, central nervous system disease, or peripheral nerve damage.
  • the composition for preventing or improving skeletal muscle atrophy of the present invention may be used to prevent or treat motor function decline or motor impairment.
  • it includes, but is not limited to, long-term stable bed rest, cast immobilization due to fractures, etc., and prevention or treatment of motor disorders or motor syndromes caused by disease, aging, etc.
  • the use is in humans or non-human animals, and does not distinguish between therapeutic and non-therapeutic uses.
  • non-therapeutic is a concept that does not include medical practice, that is, treatment of the human body according to treatment.
  • the cultivated or commercially available type of Aster for the production of Aster aster extract can be used without limitation.
  • the roots, leaves, stems, etc. of Asteria serrata can be used to prepare the extract, but leaves are preferably used.
  • the extract can be obtained by adding 1 to 10 times the volume of solvent, preferably 5 to 8 times the weight of the Aster leaf, allowing complete immersion, and then extracting three times.
  • the extraction solvent may be one or more solvents selected from water, alcohols having 1 to 4 carbon atoms, and mixed solvents thereof, preferably methanol or ethanol, but is not limited thereto.
  • the Sagebrush extract of the present invention can be extracted according to a conventional method known in the art for extracting extracts from natural products, that is, using a conventional solvent under conventional conditions of temperature and pressure.
  • the Sagebrush extract is a group consisting of water, alcohol with 1 to 4 carbon atoms, n-hexane, ethyl acetate, acetone, butylacetate, 1,3-butylene glycol, methylene chloride, and mixed solvents thereof. It can be extracted using one or more solvents selected from, preferably an alcohol having 1 to 4 carbon atoms, more preferably ethanol or methanol.
  • the method of extracting extract from Asterium vulgaris can be extracted through various methods such as hot water extraction, cold needle extraction, reflux extraction, and ultrasonic extraction, but is not limited to this, and preferably the cold needle extraction method can be used. there is.
  • the prepared extract can then be filtered, concentrated, or dried to remove the solvent. Filtering, concentrated, and dried can all be performed, and the filtration, concentrated, or dried process can be performed several times. For example, filtration may be performed using filter paper or a reduced pressure filter, concentration may be performed using a reduced pressure concentrator, and drying may be performed using a spray drying method, freeze drying method, etc., but is not limited thereto.
  • the extract extracted with the above solvent may be further subjected to a fractionation process with a solvent selected from the group consisting of butanol, n-hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water, and mixtures thereof. , but is not limited to this.
  • the pharmaceutical composition of the present invention may further include appropriate carriers, excipients, or diluents commonly used in the preparation of pharmaceutical compositions.
  • the composition containing a pharmaceutically acceptable carrier may be in various oral or parenteral dosage forms. When formulated, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • Solid preparations for oral administration may include tablets, powders, granules, capsules, etc. These solid preparations include one or more compounds and at least one excipient, such as starch, calcium carbonate, sucrose, or lactose. It can be prepared by mixing (lactose), gelatin, etc.
  • Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups.
  • simple diluents such as water and liquid paraffin
  • various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. there is.
  • Preparations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable esters such as ethyl oleate.
  • injectable esters such as ethyl oleate.
  • a base for suppositories witepsol, macrogol, tween 61, cacao, laurel, glycerogelatin, etc. can be used.
  • the pharmaceutical composition of the present invention is not limited thereto, but includes tablets, pills, powders, granules, capsules, suspensions, oral solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, and freeze-dried preparations. and a suppository.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) depending on the desired method, and the dosage depends on the condition of the patient (or individual). It varies depending on body weight, disease severity, drug type, administration route and time, but may be appropriately selected by a person skilled in the art.
  • the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type, severity, activity of the drug, and the type and severity of the patient's disease. It can be determined based on factors including sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, drugs used simultaneously, and other factors well known in the medical field.
  • the pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art.
  • the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, gender, condition, weight, absorption of the active ingredient in the body, inactivation rate and excretion rate, type of disease, and concomitant drug.
  • 0.001 to 150 mg per 1 kg of body weight preferably 0.01 to 100 mg, may be administered every day or every other day, or divided into 1 to 3 times per day.
  • the above dosage does not limit the scope of the present invention in any way.
  • the present invention may be processed pet food or animal feed as pet food, or animal medicine.
  • composition of the present invention can be used alone or in combination with surgery, hormonal treatment, chemical treatment, and methods using biological response modifiers for the prevention and treatment of skeletal muscle atrophy.
  • the present invention relates to a food composition for preventing or improving skeletal muscle atrophy containing Asterium vulgaris extract as an active ingredient.
  • the food composition for preventing or improving skeletal muscle atrophy according to one embodiment of the present invention, can be used as a health functional food that can be consumed on a daily basis to inhibit muscle aging or improve exercise function.
  • 'health functional food' refers to a food prepared by adding the Aquila extract of the present invention to food materials such as beverages, teas, spices, gum, and confectionery, or by encapsulating, powdering, or suspending it, and ingesting it.
  • food materials such as beverages, teas, spices, gum, and confectionery, or by encapsulating, powdering, or suspending it, and ingesting it.
  • the health functional food of the present invention obtained in this way is very useful because it can be consumed on a daily basis.
  • the food composition according to the present invention includes all foods such as beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, ice cream, alcoholic beverages, and vitamin complexes. Although it cannot be uniformly defined as it varies depending on the type of food, it can be added within a range that does not damage the original taste of the food, and is usually in the range of 0.01 to 50% by weight, preferably 0.1 to 20% by weight, relative to the target food. In addition, in the case of foods in the form of granules, tablets, or capsules, it is usually added in the range of 0.1 to 100% by weight, preferably 5 to 100% by weight.
  • the food composition may additionally include a foodologically acceptable food additive.
  • the functional food of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients.
  • the above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural sweeteners such as thaumatin and stevia extract or synthetic sweeteners such as saccharin and aspartame can be used.
  • the ratio of the natural carbohydrate is preferably selected in the range of 0.01 to 0.04 parts by weight, preferably about 0.02 to 0.03 parts by weight, per 100 parts by weight of the health food of the present invention.
  • the functional food of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, It may contain carbonating agents used in alcohol and carbonated drinks.
  • the functional food of the present invention may contain pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These ingredients can be used independently or in combination. The ratio of these additives is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.
  • the present invention can provide a method for preventing or improving muscle disease, including the step of administering an extract of Asterium vulgaris to a subject.
  • the term “individual” may refer to any animal, including humans, that has developed or is likely to develop skeletal muscle atrophy disease.
  • the animal may be not only a human, but also a mammal such as a cow, horse, sheep, pig, goat, camel, antelope, dog, or cat that requires treatment for similar symptoms, but is not limited thereto.
  • the prevention or improvement method of the present invention may specifically include the step of administering the composition in a pharmaceutically effective amount to an individual who has developed or is at risk of developing muscle disease (environmental factors or genetic factors). .
  • the term "administration” means introducing the pharmaceutical composition of the present invention into a patient by any appropriate method, and the route of administration of the composition of the present invention is oral or parenteral as long as it can reach the target tissue. It can be administered through various routes.
  • C2C12 cells which are mouse skeletal muscle cells, were purchased from the Korea Cell Line Bank and used.
  • C2C12 cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS) and 1% antibiotics at 37°C under 5% CO 2 conditions, and the Asterium aster extract from Example 1 was added at a concentration of 50 ⁇ g (final treatment concentration). It was processed. Mitochondrial function was measured by performing XFp analysis 24 hours after treatment with the Asterium aster extract.
  • FBS fetal bovine serum
  • OCR oxygen consumption
  • XFp miniplates were washed twice with assay medium, and assay medium (final volume 180 ⁇ L) was added to the cells. The XFp miniplates were then equilibrated in a CO 2 -free incubator at 37°C for 60 min before starting the analysis. Oligomycin, FCCP (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone), antimycin A, and rotenone are injected into each drug port of the sensor cartridge + utility plate to provide CO 2- free treatment. After culturing in the incubator for 10 minutes, OCR was measured.
  • mice Forty male apolipoprotein E (ApoE) knock-out (KO) mice were used. Five-week-old mice were acclimated to experimental diet for 7 days. Then, the mice were divided into four groups and administered with a mixture of Aster extract mixed with the drinking water of the mice once per day for 4 weeks: (1) control group: saline solution, (2) 100 mg/kg/day, (3) 300 mg/kg/day, and (4) 500 mg/kg/day. After 4 weeks, the mice were sacrificed, the skeletal muscles were isolated, and the following experiments were performed. All experiments were conducted in accordance with the Animal Experiment Ethics Guidelines of Korea University Guro Hospital. The experiments complied with the Korea University Animal Research Regulations, and the protocol was conducted with the approval of the Korea University Animal Care Committee (KUIACUC-2014-40).
  • an appropriate number of coated wells were fixed in a holder, and 100 ⁇ L of standard solution or sample was added to the wells.
  • 100 ⁇ L of a PBS solution of pH 7.0-7.2 was added.
  • Add 50 ⁇ L of Stop Solution was measured at 450 nm using a microplate reader.
  • IHC experiments were performed to determine the levels of Myoglobin, MyoD, and Myostatin, which are indicators of muscle creation and breakdown within skeletal muscle. Specifically, muscle tissue slides were fixed with 4% paraformaldehyde solution for 20 minutes, reacted with 0.3% hydrogen peroxide solution for 10 minutes, and washed. After washing, the cells were blocked with normal serum solution for 1 hour. Slides were treated with primary antibody (Abcam, Cambridge, UK) for 1 hour, washed with PBS, reacted with secondary antibody for 30 minutes, and washed with PBS. After washing, the mixed VECTASTAIN ABC reagent solution was reacted with the slide for 39 minutes and washed again with PBS. Then, the slide was reacted with the DAB substrate solution until color appeared, washed with water, stained with hematoxylin, washed with water, and dried in the air.
  • primary antibody Abcam, Cambridge, UK

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention, qui a été achevée après la découverte de l'amélioration de la fonction mitochondriale des muscles squelettiques, l'inhibition de l'atrophie musculaire et les effets favorisant la synthèse musculaire d'un extrait d'Aster glehni Fr. Schm., propose l'utilisation de l'extrait d'Aster glehni Fr. Schm. pour le traitement de troubles musculaires, ainsi que son utilisation dans des produits pharmaceutiques, des produits non pharmaceutiques, des produits de parfumerie, des bio-matériaux fonctionnels et des matières alimentaires fonctionnelles pour inhiber la perte musculaire, augmenter la masse musculaire et favoriser la fonction musculaire.
PCT/KR2023/003521 2022-03-18 2023-03-16 Composition pour la prévention et le traitement d'oedème inflammatoire, comprenant un extrait d'aster glehni fr schm. comme principe actif Ceased WO2023177234A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2022-0034230 2022-03-18
KR1020220034230A KR102755798B1 (ko) 2022-03-18 2022-03-18 섬쑥부쟁이 추출물을 유효성분으로 포함하는 근육질환 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2023177234A1 true WO2023177234A1 (fr) 2023-09-21

Family

ID=88024064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/003521 Ceased WO2023177234A1 (fr) 2022-03-18 2023-03-16 Composition pour la prévention et le traitement d'oedème inflammatoire, comprenant un extrait d'aster glehni fr schm. comme principe actif

Country Status (2)

Country Link
KR (1) KR102755798B1 (fr)
WO (1) WO2023177234A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250149376A (ko) * 2024-04-09 2025-10-16 한국과학기술연구원 섬 쑥부쟁이 추출물 또는 이의 분획물을 유효성분으로 포함하는 골 질환 개선, 예방 또는 치료용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120067183A (ko) * 2010-12-15 2012-06-25 상지대학교산학협력단 섬쑥부쟁이 추출물, 이의 분획물, 또는 이로부터 분리된 화합물을 함유하는 항경련용 조성물
KR102048430B1 (ko) * 2018-05-28 2019-11-27 (주)뉴트리 해국 추출물을 포함하는 근육 질환 예방, 개선 또는 치료용, 또는 근 기능 개선용 조성물
KR102050774B1 (ko) * 2017-08-14 2019-12-02 충남대학교산학협력단 세레브론 단백질 또는 이를 코딩하는 유전자를 포함하는 근육 손상으로 유도된 근육 질환의 예방 또는 치료용 조성물
KR102056300B1 (ko) * 2017-04-27 2020-01-22 고려은단주식회사 섬쑥부쟁이 추출물을 포함하는 인지 또는 기억력 개선용 조성물
KR20210007686A (ko) * 2019-07-12 2021-01-20 코스맥스바이오 주식회사 산나물 추출물을 유효성분으로 하는 근육관련 질환 예방 또는 치료, 근기능 개선 또는 운동수행능력 개선용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101523820B1 (ko) 2012-10-08 2015-05-28 상지대학교산학협력단 섬쑥부쟁이 추출물을 유효성분으로 함유하는 비만 또는 대사성질환의 예방 또는 치료용 약학적 조성물
KR102327847B1 (ko) 2019-12-31 2021-11-18 한국콜마주식회사 인동덩굴 추출물 및 섬쑥부쟁이 추출물을 유효성분으로 포함하는 피부 보습용 화장료 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120067183A (ko) * 2010-12-15 2012-06-25 상지대학교산학협력단 섬쑥부쟁이 추출물, 이의 분획물, 또는 이로부터 분리된 화합물을 함유하는 항경련용 조성물
KR102056300B1 (ko) * 2017-04-27 2020-01-22 고려은단주식회사 섬쑥부쟁이 추출물을 포함하는 인지 또는 기억력 개선용 조성물
KR102050774B1 (ko) * 2017-08-14 2019-12-02 충남대학교산학협력단 세레브론 단백질 또는 이를 코딩하는 유전자를 포함하는 근육 손상으로 유도된 근육 질환의 예방 또는 치료용 조성물
KR102048430B1 (ko) * 2018-05-28 2019-11-27 (주)뉴트리 해국 추출물을 포함하는 근육 질환 예방, 개선 또는 치료용, 또는 근 기능 개선용 조성물
KR20210007686A (ko) * 2019-07-12 2021-01-20 코스맥스바이오 주식회사 산나물 추출물을 유효성분으로 하는 근육관련 질환 예방 또는 치료, 근기능 개선 또는 운동수행능력 개선용 조성물

Also Published As

Publication number Publication date
KR20230136446A (ko) 2023-09-26
KR102755798B1 (ko) 2025-01-21

Similar Documents

Publication Publication Date Title
WO2014058142A1 (fr) Composition pharmaceutique contenant un extrait d'aster glehni en tant que principe actif pour la prévention et le traitement de l'obésité et de troubles métaboliques
WO2017014502A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par il-6 comprenant un extrait de fleur de rosa rugosa en tant que substance active
EP2644198A1 (fr) Utilisation de l'albiflorine ou d'un métabolite de celle-ci dans la lutte contre l'anxiété et pour l'amélioration de troubles du sommeil
WO2023177234A1 (fr) Composition pour la prévention et le traitement d'oedème inflammatoire, comprenant un extrait d'aster glehni fr schm. comme principe actif
WO2019172668A1 (fr) Nouvelle utilisation d'extrait de maydis stigma dans la prophylaxie et la thérapie d'un trouble du sommeil
JP2017137296A (ja) アストロサイトのグルコース代謝活性化剤
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
KR20200052221A (ko) 시호 추출물 또는 이의 성분을 포함하는 통증 치료, 완화 또는 예방용 조성물
WO2023042959A1 (fr) Composition anti-inflammatoire comprenant une composition de ginsénoside complexe
KR101545843B1 (ko) 유산균 발효 천마 추출물을 포함하는 수면유도 조성물
KR102783323B1 (ko) 백서향 추출물을 유효성분으로 함유하는 치주질환 예방 또는 치료용 조성물
WO2018030650A1 (fr) Composition anti-obésité contenant un extrait de feuilles de chrysanthème en tant que principe actif
WO2018008973A1 (fr) Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique
KR20230017676A (ko) 해동피 추출물을 유효성분으로 포함하는 골다공증의 예방 또는 치료용 조성물
WO2021085741A1 (fr) Composition d'amélioration ou de traitement de la maladie d'alzheimer comprenant comme principe actif du tetragonia tetragonioides
WO2011132831A1 (fr) Utilisation de la glutamine pour la prévention, le traitement ou le diagnostic d'une dépression
WO2014038878A2 (fr) Composition pour protection des neurones du cerveau et prévention, soulagement ou traitement des maladies du cerveau comprenant du musc de rat musqué
KR102602269B1 (ko) 시링가레시놀(Syringaresinol)과 레스베라트롤(Resveratrol)을 포함하는 근육 질환 예방 또는 치료용 조성물
KR102612099B1 (ko) 흑미 호분 추출물을 포함하는 스트레스 개선용 건강기능식품
WO2025121471A1 (fr) Composition pharmaceutique pour prévenir ou soulager la sarcopénie comprenant un extrait de feuille de soja
KR20120110264A (ko) 아미노쿠마린계 화합물을 유효성분으로 함유하는 골대사 질환 예방 또는 치료용 조성물
WO2017142255A1 (fr) Composition contenant un extrait de plante médicinale comme principe actif pour la prévention, l'atténuation ou le traitement du stress ou de la dépression
WO2018160021A1 (fr) Composition contenant un extrait d'oxya chinensis sinuosa ou un composé isolé de celui-ci en tant que principe actif, pour la prévention, le soulagement ou le traitement des rides cutanées
WO2023239222A1 (fr) Composition de réduction de graisse corporelle contenant des extraits de taraxacum platycarpum et de lonicerae japonica en tant que principes actifs
KR20250061073A (ko) 칸나비디올 및 어성초 추출물을 포함하는 백반증 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23771113

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23771113

Country of ref document: EP

Kind code of ref document: A1